The Economic Times daily newspaper is available online now.

    Hot Stocks: Brokerages on HPCL, Manappuram Finance, Dr Lal Pathlabs and Lupin

    Synopsis

    Jefferies maintained an underperform rating on Hindustan Petroleum Corporation Limited (HPCL) citing weak marketing and transitory refining weakness. CLSA retained a buy rating on Manappuram Finance as yields fell but growth became visible. Credit Suisse upheld an underperform rating on Dr Lal Pathlabs despite the likelihood of short-term growth favored by geographical diversification and higher pricing.

    Hot Stocks: Brokerages on HPCL, Manappuram Finance, Dr Lal Pathlabs and LupiniStock
    Global brokerage Jefferies maintained an underperform rating on HPCL while CLSA retained its buy rating on Manappuram Finance. Credit Suisse has an underperform rating on Dr Lal Pathlabs, and Morgan Stanley upgraded Lupin to overweight post March quarter results.

    We have collated a list of recommendations from top brokerage firms from ETNow and other sources:

    Jefferies on HPCL: Underprform| Target Rs 205
    Jefferies maintained an underperform rating on HPCL with a target price of Rs 205. The refining business did better than expected in Q4, it observed.

    "Marketing missed estimates, and refining weakness is transitory. There are early signs of recovery," it added.

    The global investment bank sees a possibility of a price cut in diesel/gasoline before key state elections in December.

    CLSA on Manappuram Finance: Buy| Target Rs 140
    CLSA maintained a buy rating on Manappuram Finance with a target price of Rs 140. Finally, some growth is visible after two-quarters of gold loans but yields fell.

    The global investment bank expects Manappuram to deliver single-digit loan growth with modestly improving spreads.

    Credit Suisse on Dr Lal Pathlabs: Underperform| Target Rs 1600
    Credit Suisse maintained an underperform rating on Dr. Lal Pathlabs with a target price of Rs 1600. The near-term growth is likely to be aided by geographical diversification and higher pricing.

    The global investment bank holds 'Underperform' owing to the declining trajectory of its EBITDA margin, said the note.

    Morgan Stanley on Lupin: Overweight| Target Rs 918
    Morgan Stanley upgraded Lupin to Overweight with a target price of Rs 918. The core business has started to show margin improvement from a low base, it said.

    "Visibility of high-quality new launches like gSpiriva. FY24 can be a turnaround year for Lupin," said the note.

    (Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of Economic Times)
    Experience Your Economic Times Newspaper, The Digital Way!
    • Front Page
    • Pure Politics
    • ET Markets
    • Smart Investing
    • More
      (What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)

      Download The Economic Times News App to get Daily Market Updates & Live Business News.

      Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
      ...more
      The Economic Times

      Stories you might be interested in